Disclosure notice in Eurocine Vaccines

Eurocine Vaccines hereby announces that Flerie Invest AB has acquired shares in the company and holds above 10 % of the shares in the company. Flerie Invest AB holds approximately 12.55 % of the votes and capital. Further, Eurocine Vaccines announces that Formue Nord Markedsneutral A/S has decreased its holdings to approximately 3.09 % of the votes and capital.

Flerie Invest AB has acquired approximately 12.55 % of the votes and capital in Eurocine Vaccines. Flerie Invest AB is an investment company within the biotechnology and life science sector with offices in Stockholm and London. The company was founded in 2010 by Thomas Eldered, co-founder of Recipharm.

Further, Eurocine Vaccines announces that Formue Nord Markedsneutral A/S has decreased its holdings to approximately 3.09 % of the votes and capital.

Hans Arwidsson, Ph.D., MBA

CEO of Eurocine Vaccines AB
hans.arwidsson@eurocine-vaccines.com

+46 70 634 0171

Eurocine Vaccines is a development company in the highly intense vaccine area, bridging the gap between innovation and market.

Through its portfolio strategy, innovative vaccine candidates are given the opportunity to reach the market quicker, while investors are offered risk diversification with a big future leverage. These candidates are later licensed to partners for commercialization.

The company is in the possession of its own technology platform, Endocine™, which has been tested in four extensive clinical studies with over 400 subjects.

Listed at Spotlight Stock Market, XSAT, Eurocine Vaccines, EUCI, today operates at the heart of the bio-scientific cluster of Karolinska Institutet, Solna, Sweden and has attracted several internationally merited vaccine specialists to its board.